Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | PRSS12 | P56730 | 6/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7516257 | 0.81 | ALDH1A1 (0.51) | RHEBCHEK2PTGDR2MAPTPPARG | |
| SCHEMBL30943399 | 0.73 | RHEB (0.69) | RHEBCHEK2DGAT1PRSS12NPC1 | |
| SCHEMBL10736415 | 0.73 | RHEB (0.69) | RHEBCHEK2DGAT1PRSS12NPC1 | |
| Iodide SCHEMBL27236943 | 0.72 | RHEB (0.67) | RHEBCHEK2DGAT1PRSS12NPC1 | |
| SCHEMBL2714424 | 0.71 | RHEB (0.71) | RHEBCHEK2PRSS12 | |
| SCHEMBL2715938 | 0.71 | RHEB (0.71) | RHEBCHEK2PRSS12 | |
| SCHEMBL7516823 | 0.71 | IGF1R (0.56) | RHEBNPC1RAB9A | |
| SCHEMBL7516825 | 0.71 | IGF1R (0.56) | RHEBNPC1RAB9A | |
| SCHEMBL25206796 | 0.70 | RHEB (0.69) | RHEBCHEK2NPC1MAPTRAB9A | |
| SCHEMBL6324494 | 0.70 | RHEB (0.69) | RHEBNPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | RHEB 1710/4885CA2 3938/4885CHEK2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.